Skip to main content

Advertisement

SpringerLink
Log in

Glioma: What is the role of c-Myc, hsp90 and telomerase?

  • Review
  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The continuous advancements in cancer research have contributed to the overwhelming evidence of the presence of telomerase in primary and secondary tumours together with hsp90 and c-Myc. This review will discuss the important role of telomerase together with hsp90 and c-Myc within the initiation and progression of gliomas. Also it will review the differential expression of these genes in the different grades of gliomas and the possibility of new treatments targeting these specific genes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Darling J: In Vitro Culture of Malignant Brain Tumors. In R. Pfragner, I. Freshney (eds). Culture of Human Tumor Cells Wiley-Liss, Inc. Verlag GmbH 2003, (pp 349–372)

  2. Cooper N: Cancer Survival: England and Wales. Office for National Statistics 2004

  3. Behin A, Hoang-Xuan K, Carpentier A, Delattre J: Primary brain tumours in adults. The Lancet 361: 323–331, 2003

    Article  Google Scholar 

  4. Maher E, Furnari F, Bachoo R, Rowitch D, Louis D, Cavenee W, DePinho R: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311–1333, 2001

    Article  CAS  PubMed  Google Scholar 

  5. Kleihues P, Cavenee K: Pathology and genetics of tumour of the nervous system. In FA Tavassoli and P Devilee (eds). Classification of Tumours. International Agency for Research on Cancer (IARC), World Health Organization (WHO), IARC Press: Lyon. 2000 (pp. 172–174)

  6. Wessels P, Weber W, Raven G, Ramaekers F, Hopman A, Twijnstra A: Supratentorial grade II astrocytoma: biological features and clinical course. The Lancet 2: 395–403, 2003

    Google Scholar 

  7. Guo D: The identification and characterisation of LRIG gene family and its expression in astrocytic tumours. Umea University medical dissertations, 2004

  8. Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, Kuratsu J, Ushio Y: Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95: 249–257, 2002

    Article  CAS  PubMed  Google Scholar 

  9. Castro M, Cowen R, Williamson I., David A, Jimenez-Dalmaroni M, Yuan X, Bigliari A, Williams J, Lowenstein P: Current and future strategies for the treatment of malignant brain tumours. Pharm Therap 98: 71–108, 2003

    CAS  Google Scholar 

  10. Louis D, Cavenee W: Cancer: V. DeVita, S. Hellman, S. Rosenberg (eds). Principles and Practice of Oncology. Lippincott-Raven, Philadelphia, 1997 (pp. 2013–2021)

  11. Lang FF, Miller DC, Koslow M: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427–436, 1994

    CAS  PubMed  Google Scholar 

  12. Tremont-Lukats I, Gilbert M: Advances in molecular therapies in patients with brain tumors Cancer Control 10: 125–138, 2003

    PubMed  Google Scholar 

  13. Smogorzewska A, Steensel B, Bianchi A, Oelmann S, Schaefer M, Shnapp G, Lange T. Control of human telomere length by TRF1 & TRF2. Mol Cell Biol 20: 1659–1668, 2000

    Google Scholar 

  14. Mergny J, Riou J, Mailliet P, Teulade-Fichou M, Gilson E: Natural and pharmacological regulation of telomerase. Nucleic Acids Research 30: 839–865, 2002

    Google Scholar 

  15. Sharpless N, DePinho R: Telomeres, stem cells, senescence and cancer. J Clin Invest 113: 160–168, 2004

    Article  CAS  PubMed  Google Scholar 

  16. Masutomi K, Hahn W: Telomerase and tumorigenesis. Cancer letters 194: 163–172, 2003

    Article  CAS  PubMed  Google Scholar 

  17. Ahmed A., Tollefsbol T: Telomeres, telomerase, and telomerase inhibition: clinical implications for cancer. J American Geriatrics Society 51: 116–122, 2003

    Google Scholar 

  18. Chang J, Chen Y, Yang H, Chen C, Cheng A: Differential regulation of telomerase activity by six telomerase subunits. Eur J Biochem 269: 3442–3450, 2002

    Article  CAS  PubMed  Google Scholar 

  19. Siyuan L, Zhu JJ, Anthony DC, Greider CW, Black PM: Telomerase activity in human gliomas. Neurosurg 42: 1120–1121, 1998

    Google Scholar 

  20. Harada K, kurisu K, Tahara H, Tahara E, Ide T, Tahara E: Telomerase activity in primary and secondary glioblastomas multiforms as a novel molecular tumour marker. J Neurosurg 93: 618–625, 2000

    CAS  PubMed  Google Scholar 

  21. Reddle R, Bearss D, Hurley L: Telomeres and telomerase as drug targets. Current Opinion in Pharmacology 2: 415–423, 2002

    Google Scholar 

  22. Höhfeld J, Cyr D, Patterson C: From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Reports 2: 885–890, 2001

    Google Scholar 

  23. Pockley G: Heat shock proteins in health and disease: therapeutic targets or therapeutic agents? Expert reviews in molecular medicine 2001: 1–20. 2001

  24. Anderson KM., Srivastava PK: Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses. Immunology Letters 74: 35–39, 2000

    Article  CAS  PubMed  Google Scholar 

  25. Buchner JS. Mayr BC, Jakob U: Purification and characterisation of prokaryotic and eukaryotic Hsp90. Methods of Enzymology 290: 409–418, 1998

    CAS  Google Scholar 

  26. Pratt W. Galigniana MD, Harrell JM, DeFranco DB: Role of Hsp90 and the Hsp90-binding immunophilins in signalling protein movement. Cellular Signalling 16: 857–872, 2004

    Article  CAS  PubMed  Google Scholar 

  27. Pratt W, Toft D: Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Experimental Biology and Medicine 228: 111–133, 2003

    CAS  PubMed  Google Scholar 

  28. Weikl T, Buchner J, Bügl H, Pirkl F, Bose S: Purification of Hsp90 partner proteins Hop/p60, p23, and FKBP52. Methods of Enzymology 290: 418- 429, 1998

    Google Scholar 

  29. Sreedhar A, Csermely P: Heat shock proteins in the regulation of apoptosis: new strategies in tumour therapy. Pharmacology and therapeutics 101: 227–257, 2004

    Article  CAS  PubMed  Google Scholar 

  30. Chiosis G, Vilenchik M, Kim J, Solit D: Hsp90: the vulnerable chaperone. Drug Discov Today 9: 881–888, 2004

    Article  CAS  PubMed  Google Scholar 

  31. Schulte T, Blagosklonny M, Ingui C, Neckers L: Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270: 24585–24588, 1995

    CAS  PubMed  Google Scholar 

  32. Yang J, Yang M, Iannone M, Shih WJ, Lin Y, Hait WN: Disruption of the EF-2 Kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Research 61: 4010–4016, 2001

    CAS  PubMed  Google Scholar 

  33. Nomura M, Nomura N, Newcomb EW, Lukyanov Y, Tamasdan C, Zagzag D: Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells. J Cell Physiol 201: 374–384, 2004

    Article  CAS  PubMed  Google Scholar 

  34. Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer I.A: Interaction of Hsp90 with the Nascent Form of the Mutant Epidermal Growth Factor Receptor EGFRvIII. J Biol Chem 278: 5292–5299, 2002

    PubMed  Google Scholar 

  35. Haendeler J, Hoffmann J, Rahman S, Zeiher AM, Dimmeler S: Regulation of Telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylation. Federation of European Biochemical Societies 536: 180–186, 2003

    CAS  Google Scholar 

  36. Roninson I: Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Letters 179: 11–14, 2002

    Article  Google Scholar 

  37. Helt C, Staversky R, Lee Y, Bambara R, Keng P, O'Reilly M: The Cdk and PCNA domains on p21Cip1 both function to inhibit G1/S progression during hyperoxia. Am J. Physiol Lung Cell Mol Physiol 286: 506–513, 2004

    Google Scholar 

  38. Kanzawa T, Germano I, Kondo Y, Ito H, Kyo S, Kondo S: Inhibition of telomerase activity in malignant glioma cell lines correlates with their sensitivity to TMZ. Br J Cancer 89: 22–29, 2003

    Article  Google Scholar 

  39. Zörnig M, Evan G: Cell cycle: on target with Myc. Current Biology. 6: 1553–1556, 1996

    PubMed  Google Scholar 

  40. Levens D: Reconstructing MYC. Genes Development 17: 1071–1077, 2003

    CAS  PubMed  Google Scholar 

  41. Packham G, Cleveland J: c-Myc and apoptosis. Biochimica et Biophysica Acta 1242: 11–28, 1995

    PubMed  Google Scholar 

  42. Lavigne P, Crump MP, Gagné S, Hodges R, Kay C, Sykes B: Insights into the mechanism of heterodimerization from the H-NMR solution structure of the c-Myc/Max heterodimeric leucine zipper. J Mol Biol 281: 165–181, 1998

    Article  CAS  PubMed  Google Scholar 

  43. Pelengaris S, Khan M: The many faces of c-Myc. Arch Biochem Biophys. 416: 129–36, 2003

    Article  CAS  PubMed  Google Scholar 

  44. Dang C: C-Myc target genes involved in cell growth, apoptosis, and metabolism. Molecular and Cellular Biology 19: 1–11, 1999

    CAS  PubMed  Google Scholar 

  45. Lutz W, Leon J, Eilers M: Contribution of Myc to tumorgenesis. Biochimica et Biophysica Acta 1602: 61–71, 2002

    CAS  PubMed  Google Scholar 

  46. Oh S., Song Y, Kim U, Yim J, Kim T: In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells. Biochem Biophys Res Commun 263: 361–365, 1999

    Article  CAS  PubMed  Google Scholar 

  47. Abba M., LaguensR., Dulout F., Golijow C: The c-myc activation in cervical carcinomas and HPV 16 infections. Mutation Research 557: 151–158, 2004

    CAS  PubMed  Google Scholar 

  48. Sagawa Y, Nishi H, Isaka K, Fujito A, Takayama M: The correlation of TERT expression with c-Myc expression in cervical cancer. Cancer Letters 168: 45–50, 2001

    Article  CAS  PubMed  Google Scholar 

  49. Hsu C, Miaw J, Hsia J, Shai S, Chen C: Concordant expression of the telomerase-associated genes in non-small cell lung cancer. EJSO 29: 594–599, 2003

    PubMed  Google Scholar 

  50. Zhang G, Gu Y, Zhao Z, Xu S, Zhang H, Wang H, Hao B: Coordinate increase of telomerase activity and c-Myc expression in Helicobacter pylori-associated gastric diseases. World J Gastroenterol 10: 1759–1762, 2004

    CAS  PubMed  Google Scholar 

  51. Chrzan P, Skokowski J, Karmolinski A, Pawelczyk T: Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clinical Biochemistry 34: 557–562, 2001

    Article  CAS  PubMed  Google Scholar 

  52. Pallini, R., Pierconti, F., Falchetti, M., D'Arcangelo, D., Fernandez, E., Maira, G., D'Ambrosio, E., Larocca, L. Evidence for telomerase involvement in the angiogenesis of astrocytic tumours: expression of human telomerase reverse transcriptase messenger RNA by vassculatr endothelial cells. J Neurosurg 94: 961–771, 2001

    Google Scholar 

  53. Chen C, Tsai N, Liu Y, Ho L, Hsieh H, Yen C, Harn H: Telomerase activity in human hepatocellular carcinoma: parallel correlation with human telomerase reverse transcriptase (hTERT) mRNA isoforms but not with cell cycle modulators or c-Myc expression. EJSO 28: 225–234, 2002

    PubMed  Google Scholar 

  54. Herms J, von Loewenich F, Behnke J, Markakis E, Kretzschmar H: c-Myc oncogene family expression in glioblastoma and survival. Surg Neurol 51: 536–542, 1999

    CAS  PubMed  Google Scholar 

  55. Huang H., Colella S, Kurrer M, Yonekawn Y, Kleihues P, Ohgaki H:. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Research 60: 6868–6874, 2000

    Google Scholar 

  56. Kiaris H, Schally A: Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA 96: 226–231, 1999

    CAS  PubMed  Google Scholar 

  57. Miracco C, De Santi M, Luzi P, Lalinga A, Laurini L, De Nisi M, Angeloni G, Brogi M, Cardone C, Carducci A., Arcuri F, Tosi P, Rubino G, Pirtoli L: In situ detection of telomeres by fluorescence in situ hybridization and telomerase activity in glioblastoma multiforme: correlation with p53 status, EGFR, c-Myc, M1B1 and topoisomerase IIa protein expression. Int J Oncology 23: 1529–1535, 2003

    CAS  Google Scholar 

  58. Hau PU, Baumgart K, Pfeifer A. BockT, Jauch J, Dietrich K, Fabel O, Grauer C, Wismeth M, Klinkhammer-Schalke M, Allgäuer G, Schierer H, Koch J, Schlaier W, Ulrich A, Brawanski U, Bogdahn A, Steinbrecher: Salvage therapy in patients with glioblastoma; is there any benefit? Cancer 98: 2678–2686, 2003

  59. Quinn M, Babb P, Brock A, Kirby L, Jones J: Cancer trends in England and Wales, 1950–1999. Studies on Medical and Population Subjects No. 66. London. The Stationery Office.

  60. White I, Wright W, Shay J: Telomerase inhibitors. Trends Biotechnol 59: 114–120, 2001

    Google Scholar 

  61. Natarajan S, Chen N, Wancewicz E, Monia P, Corey D: Oligonucleotide. 14: 263–273, 2004

    Google Scholar 

  62. Kondo Y, Komata T, Kondo S: Combination therapy of 2–5A antisense telomerase RNA and ciplatin for malignant glioma. Int J Oncol 18: 1287–1292, 2001

    CAS  PubMed  Google Scholar 

  63. Mukai S, Kondo Y, Koga S, Komata T, Barna B, Kondo S: 2–5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Research 60: 4461–4467, 2000

    CAS  PubMed  Google Scholar 

  64. Kelland L: Telomerase inhibitors: targeting the vulnerable end of cancer. Anticancer Drugs 11: 503–513, 2000

    Article  CAS  PubMed  Google Scholar 

  65. Odago F, Gerson S: Telomerase inhibition and telomere erosion: a two-pronged strategy in cancer therapy. Trends in Pharmacological Sciences 24: 328–331, 2003

    Article  CAS  PubMed  Google Scholar 

  66. Holt S, Aisner D, Baur J, Tesmer V, Dy M, Ouellette M, Trager J, Morin G, Tort D, Shay J, Wright W, White M: Functional requirements of p23 and hsp90 in telomerase complexes. Genes Dev 13: 817–826, 1999

    CAS  PubMed  Google Scholar 

  67. Kamal AM, Boehm F, Burrows FJ: Therapeutic and diagnostic implications of Hsp90 activation. Trends in Molecular Medicine 10: 283–290, 2004

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Sciences, University of Central Lancashire, Preston, UK

    A. Shervington, N. Cruickshanks, H. Wright, R. Atkinson-Dell, R. Lea & L. Shervington

  2. Consultant Neurosurgeon, Royal Preston Hospital, Preston

    G. Roberts

Authors
  1. A. Shervington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Cruickshanks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Atkinson-Dell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Lea
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Shervington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Shervington.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shervington, A., Cruickshanks, N., Wright, H. et al. Glioma: What is the role of c-Myc, hsp90 and telomerase?. Mol Cell Biochem 283, 1–9 (2006). https://doi.org/10.1007/s11010-006-2495-z

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-006-2495-z

Key Words

Search

Navigation